Radiation therapy for the treatment of locally advanced and metastatic prostate cancer (Q34348253)

1 August 2017

1 reference

title

Radiation therapy for the treatment of locally advanced and metastatic prostate cancer (English)

1 reference

adaptive radiation therapy

1 August 2017

main subject

0 references

1 reference

Thurman SA

1

1 reference

1 August 2017

Ramakrishna NR

series ordinal

2

1 reference

1 August 2017

DeWeese TL

series ordinal

3

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Hematology / Oncology Clinics of North America

1 August 2017

published in

1 reference

1 August 2017

volume

15

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

423-443

1 reference

Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Focal therapy for prostate cancer 1996: maximizing outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Potential benefit of improved local tumor control in patients with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

In vitro radiation sensitivity of the LNCaP prostatic tumor cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

PTEN/MMAC1/TEP1 involvement in primary prostate cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

External beam radiotherapy dose response of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metast

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Radiotherapy for high grade clinically localized adenocarcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970224-0

7 January 2021

10.1016/S0889-8588(05)70224-0

Identifiers

DOI

1 reference

1 August 2017

1 reference